Imaging Science in Dentistry

Korean Academy of Oral and Maxillofacial Radiology (대한영상치의학회)
권호 표지
DOI QR코드

DOI QR Code

Imaging aspects of maxillomandibular bone alterations in patients with multiple myeloma treated with bisphosphonates: A systematic review

  • Received : 2024.02.22
  • Accepted : 2024.06.18
  • Published : 2024.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Multiple myeloma (MM) is a rare cancer that is typically managed with bisphosphonates to slow bone resorption and prevent skeletal complications. This study aimed to identify imaging patterns in MM patients receiving bisphosphonate therapy. Materials and Methods: This systematic review included studies investigating maxillomandibular bone alterations based on imaging examinations in MM patients treated with bisphosphonates. The selected studies were qualitatively assessed using the Critical Appraisal Tools from SUMARI. Results: Six studies, involving 669 MM patients, were included, with 447 receiving bisphosphonate treatment. The majority were treated with pamidronate, zoledronate, or a combination of both. Seventy patients developed medication-related osteonecrosis of the jaw (MRONJ), predominantly in the mandible, characterized by the presence of bony sequestrum, bone sclerosis, increased periodontal ligament space, osteolytic lesions, and osteomyelitis as observed in imaging analyses. For non-MRONJ lesions, the mandible also exhibited the highest frequency of asymptomatic bone alterations. These ranged from "punched-out" osteolytic lesions or "soap bubble" lesions to solitary bone lesions, areas of bone sclerosis, abnormalities of the hard palate, osteoporosis, non-healed alveoli, and cortical bone rupture. Conclusion: MM patients treated with bisphosphonates display radiographic patterns of maxillomandibular bone lesions. These patterns aid in diagnosis and facilitate early and targeted treatment, thereby contributing to improved morbidity outcomes for these patients.

Keywords

Acknowledgement

We would like to thank the support received from Maranhao Cancer Hospital during the conduction of this research.

References

  1. Tas Ozyurtseven B, Serin I, Nursal AF, Pehlivan S, Pehlivan M. Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience. BMC Oral Health 2021; 21: 272.
  2. Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci(Basel). 2021; 9: 3.
  3. Tanveer N, Hussein S, Pingili S, Makkena VK, Jaramillo AP, Awosusi BL, et al. Multiple myeloma and the role of bisphosphonates in its management. Cureus 2023; 15: e45270.
  4. Ali SA, Khalifa HM, Bayoumi A, AlMazrooa S, Bin Madi NO, Akeel S, et al. Osteolytic lesion of the maxilla in an undiagnosed multiple myeloma patient identified incidentally by cone beam computed tomography. Am J Case Rep 2022; 23: e936585.
  5. Faria KM, Ribeiro AC, Brandao TB, Silva WG, Lopes MA, Pereira J, et al. Radiographic patterns of multiple myeloma in the jawbones of patients treated with intravenous bisphosphonates. J Am Dent Assoc 2018; 149: 382-91. https://doi.org/10.1016/j.adaj.2017.12.028
  6. Feitosa EF, Vasconcellos MM, Magalhaes RJ, Domingos-Vieira AC, Visconti MA, Guedes FR, et al. Bisphophonate alterations of the jaw bones in individuals with multiple myeloma. Dentomaxillofac Radiol 2020; 49: 20190155.
  7. Jiang L, Cui X, Ma H, Tang X. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials. J Orthop Surg Res 2021; 16: 400.
  8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372.
  9. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Systematic reviews of etiology and risk (2020). In: Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z. JBI manual for evidence synthesis. JBI; 2020 [cited 2024 Feb 20]. Available from: https://synthesismanual.jbi.global. https://doi.org/10.46658/JBIMES-24-06
  10. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945-52. https://doi.org/10.1200/JCO.2005.04.2465
  11. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18: 2015-9. https://doi.org/10.1093/annonc/mdm370
  12. Wazzan T, Kashtwari D, Almaden WF, Gong Y, Chen Y, Moreb J, et al. Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients - a retrospective case control study. Spec Care Dentist 2018; 38: 356-61. https://doi.org/10.1111/scd.12318
  13. Rocha TG, Feitosa EF, Maiolino A, de Magalhaes Filho RJ, Guedes FR, Torres SR, et al. Imaginological characterization of multiple myeloma lesions of the jaws through cone-beam computed tomography. Oral Radiol 2020; 36: 168-76. https://doi.org/10.1007/s11282-019-00394-1
  14. Lu SY, Ma MC, Wang MC, Hsue SS. The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma. J Formos Med Assoc 2021; 120: 1967-76. https://doi.org/10.1016/j.jfma.2021.01.015
  15. Chatziravdeli V, Katsaras GN, Katsaras D, Doxani C, Stefanidis I, Zintzaras E. A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives. J Musculoskelet Neuronal Interact 2022; 22: 596-621.
  16. Zhong Y, Li S. New progress in improving the delivery methods of bisphosphonates in the treatment of bone tumors. Drug Des Devel Ther 2021; 15: 4939-59. https://doi.org/10.2147/DDDT.S337925
  17. Terpos E, Christoulas D, Gavriatopoulou M. Biology and treatment of myeloma related bone disease. Metabolism 2018; 80: 80-90. https://doi.org/10.1016/j.metabol.2017.11.012
  18. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws - 2022 update. J Oral Maxillofac Surg 2022; 80: 920-43. https://doi.org/10.1016/j.joms.2022.02.008
  19. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-20. https://doi.org/10.1182/blood-2007-10-116129
  20. Bacci C, Cerrato A, Dotto V, Zambello R, Barila G, Lico A, et al. The importance of alliance between hematologists and dentists: a retrospective study on the development of bisphosphonates osteonecrosis of the jaws (BRONJ) in multiple myeloma patients. Dent J(Basel) 2021; 9: 11.
  21. Wei X, Pushalkar S, Estilo C, Wong C, Farooki A, Fornier M, et al. Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. Oral Dis 2012; 18: 602-12.
  22. Stockmann P, Wehrhan F, Schwarz-Furlan S, Stelzle F, Trabert S, Neukam FW, et al. Increased human defensine levels hint at an inflammatory etiology of bisphosphonate-associated osteonecrosis of the jaw: an immunohistological study. J Transl Med 2011; 9: 135.
  23. Migliorati CA, Saunders D, Conlon MS, Ingstad HK, Vaagen P, Palazzolo MJ, et al. Assessing the association between bisphosphonate exposure and delayed mucosal healing after tooth extraction. J Am Dent Assoc 2013; 144: 406-14. https://doi.org/10.14219/jada.archive.2013.0134
  24. Almeida TM, Cavalcanti EF, Freitas AD, Magalhaes RJ, Maiolino A, Torres SR. Can dentists detect multiple myeloma through oral manifestations? Rev Bras Hematol Hemoter 2018; 40: 43-9. https://doi.org/10.1055/s-0037-1606274
  25. Terpos E, Zamagni E, Lentzsch S, Drake MT, Garcia-Sanz R, Abildgaard N, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol 2021; 22: e119-30.
  26. Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2018; 36: 812-8. https://doi.org/10.1200/JCO.2017.76.6402